Adempas: first soluble guanylate cyclase stimulator for pulmonary hypertension

Bayer has launched the first-in-class treatment Adempas (riociguat) to improve exercise capacity in adults with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Adempas (riociguat) provides a new treatment option for patient with pulmonary hypertension (pictured) | SCIENCE PHOTO LIBRARY
Adempas (riociguat) provides a new treatment option for patient with pulmonary hypertension (pictured) | SCIENCE PHOTO LIBRARY

PHARMACOLOGY

Riociguat is a soluble guanylate cyclase (sGC) stimulator which has a dual mechanism of action. It sensitises sGC to endogenous nitric oxide (NO) by stabilising binding between sGC and NO and directly stimulates sGC independently of NO.

CLINICAL STUDIES

Riociguat has been studied in two key phase III clinical trials. The PATENT-1 study evaluated riociguat in patients with symptomatic pulmonary arterial hypertension and the CHEST-1 study assessed the efficacy and safety of riociguat for the treatment of chronic thromboembolic pulmonary hypertension that was inoperable or that had persisted or recurred after pulmonary endartectomy.

In both trials, patients were randomised to receive placebo or riociguat titrated over 8 weeks to optimal individual dose (range 500 microgram to 2.5mg three times daily), which was then maintained over a further 4 weeks in PATENT-1 and 8 weeks in CHEST-1. 

The primary endpoint, placebo-adjusted change from baseline in 6-minute walk distance, was 36 metres in PATENT-1 and 46 metres in CHEST-1 (p<0.0001 for both comparisons).

Headache, hypotension, GI upset, dizziness and peripheral oedema were the most commonly reported adverse effects.

View Adempas drug record

Further information: Bayer

Follow MIMS on Twitter

Sign up for MIMS bulletins


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.